EMJ Urology 8 [Supplement 1] . 2020

In this issue

The efficacy and safety of onabotulinumtoxinA (BOTOX®, Allergan, Dublin, Ireland) in the treatment of overactive bladder syndrome (OAB) has been established in various studies and is recommended as the third-line therapy. Despite this, numerous patients who could benefit from onabotulinumtoxinA for refractory OAB are not receiving it. Patients and/or physicians have concerns and misunderstandings regarding potential post void residual (PVR).

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.